newsfilter
← Latest News
Business Wire·

Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease

Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions Etavopivat was well tolerated with a safety profile consistent with underlying sickle cell disease Clinical data in 15 patients dosed for up to 12 week